GlassScriptPhysician profile
Bethann Kast Hamm
NPI 1922002518
$3,498.99
in general payments reported to CMS, 2019-2025
27 companies · $210 in 2025
The $210 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $712 · 2020: $336 · 2021: $1,094 · 2022: $653 · 2023: $480 · 2024: $13.61 · 2025: $210.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $703.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $703.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $814.32 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Astellas Pharma US INC | $466.23 | 2020-2023 | Myrbetriq, Veozah |
| Glaxosmithkline, LLC. | $335.54 | 2019-2022 | |
| Abbvie INC. | $259.45 | 2021-2023 | |
| Astrazeneca Pharmaceuticals LP | $240.56 | 2019-2023 | Farxiga |
| Merck Sharp & Dohme LLC | $221.32 | 2019-2022 | |
| Pfizer INC. | $155.59 | 2019-2022 | |
| Lilly USA, LLC | $133.65 | 2019-2022 | |
| Abbott Laboratories | $133.06 | 2021-2023 | Freestyle Libre 3, Freestyle Libre 2 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $98.67 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $70.43 | 2019-2023 | Xifaxan, Trulance |
| Amarin Pharma, INC. | $65.92 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $53.35 | 2019-2021 | |
| Boston Scientific Corporation | $50.77 | 2021-2025 | Ams 700 |
| Amgen INC. | $46.22 | 2020-2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $45.01 | 2019-2023 | |
| Sunovion Pharmaceuticals INC. | $42.47 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $39.86 | 2019 | |
| Allergan, INC. | $39.61 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $39.29 | 2021-2023 | |
| Exact Sciences Corporation | $36.87 | 2023 | Cologuard Collection Kit |
| Biohaven Pharmaceutical Holding Company LTD. | $29.39 | 2022 | |
| Medtronic, INC. | $22.36 | 2025 | Interstim |
| Daiichi Sankyo INC. | $18.53 | 2021 | |
| Sanofi Pasteur INC. | $15.77 | 2023 | |
| Janssen Pharmaceuticals, INC | $12.50 | 2020 | |
| Kaleo, INC. | $12.25 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bethann Hamm listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.